» Articles » PMID: 34124650

Developing an Explainable Machine Learning-Based Personalised Dementia Risk Prediction Model: A Transfer Learning Approach With Ensemble Learning Algorithms

Overview
Journal Front Big Data
Publisher Frontiers Media
Date 2021 Jun 14
PMID 34124650
Citations 19
Authors
Affiliations
Soon will be listed here.
Abstract

Alzheimer's disease (AD) has its onset many decades before dementia develops, and work is ongoing to characterise individuals at risk of decline on the basis of early detection through biomarker and cognitive testing as well as the presence/absence of identified risk factors. Risk prediction models for AD based on various computational approaches, including machine learning, are being developed with promising results. However, these approaches have been criticised as they are unable to generalise due to over-reliance on one data source, poor internal and external validations, and lack of understanding of prediction models, thereby limiting the clinical utility of these prediction models. We propose a framework that employs a transfer-learning paradigm with ensemble learning algorithms to develop explainable personalised risk prediction models for dementia. Our prediction models, known as , are initially trained and tested using a publicly available dataset ( = 84,856, mean age = 69 years) with 14 years of follow-up samples to predict the individual risk of developing dementia. The decision boundaries of the best source model are further updated by using an alternative dataset from a different and much younger population ( = 473, mean age = 52 years) to obtain an additional prediction model known as the . We further apply the SHapely Additive exPlanation (SHAP) algorithm to visualise the risk factors responsible for the prediction at both population and individual levels. The best source model achieves a geometric accuracy of 87%, specificity of 99%, and sensitivity of 76%. In comparison to a baseline model, our target model achieves better performance across several performance metrics, within an increase in geometric accuracy of 16.9%, specificity of 2.7%, and sensitivity of 19.1%, an area under the receiver operating curve (AUROC) of 11% and a transfer learning efficacy rate of 20.6%. The strength of our approach is the large sample size used in training the source model, transferring and applying the "knowledge" to another dataset from a different and undiagnosed population for the early detection and prediction of dementia risk, and the ability to visualise the interaction of the risk factors that drive the prediction. This approach has direct clinical utility.

Citing Articles

Persistent homology for MCI classification: a comparative analysis between graph and Vietoris-Rips filtrations.

Bhattacharya D, Kaur R, Aithal N, Sinha N, Issac T Front Neurosci. 2025; 19:1518984.

PMID: 40078712 PMC: 11897488. DOI: 10.3389/fnins.2025.1518984.


Advancing Alzheimer's Therapy: Computational strategies and treatment innovations.

Paul J, Malik A, Azmal M, Gulzar T, Afghan M, Talukder O IBRO Neurosci Rep. 2025; 18:270-282.

PMID: 39995567 PMC: 11849200. DOI: 10.1016/j.ibneur.2025.02.002.


CAREUP: An Integrated Care Platform with Intrinsic Capacity Monitoring and Prediction Capabilities.

Kolakowski M, Lupica A, Ben Bader S, Djaja-Josko V, Kolakowski J, Cichocki J Sensors (Basel). 2025; 25(3).

PMID: 39943555 PMC: 11819908. DOI: 10.3390/s25030916.


Bias in machine learning applications to address non-communicable diseases at a population-level: a scoping review.

Birdi S, Rabet R, Durant S, Patel A, Vosoughi T, Shergill M BMC Public Health. 2024; 24(1):3599.

PMID: 39732655 PMC: 11682638. DOI: 10.1186/s12889-024-21081-9.


Life-Course Multidisciplinary Psychosocial Predictors of Dementia Among Older Adults: Results From the Health and Retirement Study.

Kuwayama S, Tarraf W, Gonzalez K, Marquez F, Gonzalez H Innov Aging. 2024; 8(11):igae092.

PMID: 39544491 PMC: 11557907. DOI: 10.1093/geroni/igae092.


References
1.
Mandrekar J . Receiver operating characteristic curve in diagnostic test assessment. J Thorac Oncol. 2010; 5(9):1315-6. DOI: 10.1097/JTO.0b013e3181ec173d. View

2.
Dyer A, Murphy C, Lawlor B, Kennelly S . Cognitive Outcomes of Long-term Benzodiazepine and Related Drug (BDZR) Use in People Living With Mild to Moderate Alzheimer's Disease: Results From NILVAD. J Am Med Dir Assoc. 2019; 21(2):194-200. DOI: 10.1016/j.jamda.2019.08.006. View

3.
Lee S, Zhou X, Gao Y, Vardarajan B, Reyes-Dumeyer D, Rajan K . Episodic memory performance in a multi-ethnic longitudinal study of 13,037 elderly. PLoS One. 2018; 13(11):e0206803. PMC: 6248922. DOI: 10.1371/journal.pone.0206803. View

4.
Cui R, Liu M . RNN-based longitudinal analysis for diagnosis of Alzheimer's disease. Comput Med Imaging Graph. 2019; 73:1-10. DOI: 10.1016/j.compmedimag.2019.01.005. View

5.
Lyketsos C, Lopez O, Jones B, Fitzpatrick A, Breitner J, DeKosky S . Prevalence of neuropsychiatric symptoms in dementia and mild cognitive impairment: results from the cardiovascular health study. JAMA. 2002; 288(12):1475-83. DOI: 10.1001/jama.288.12.1475. View